Commodore Capital’s Enliven Therapeutics ELVN Stock Holding History

Commodore Capital’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166M	Hold	3,275,000	–	–	9.9%	2
2026 Q1	$128M	Sell	3,275,000 -1,417,809	-30%	-$39.3M	7.43%	3
2025 Q4	$72.3M	Hold	4,692,809	–	–	4.81%	7
2025 Q3	$96.1M	Hold	4,692,809	–	–	4.69%	5
2025 Q2	$94.1M	Buy	4,692,809 +17,809	+0.4%	+$337K	6.64%	4
2025 Q1	$92M	Buy	4,675,000 +470,000	+11%	+$10.1M	6.78%	3
2024 Q4	$94.6M	Buy	4,205,000 +105,000	+3%	+$2.72M	6.93%	5
2024 Q3	$105M	Buy	4,100,000 +126,755	+3%	+$2.94M	6.54%	5
2024 Q2	$92.9M	Hold	3,973,245	–	–	6.34%	5
2024 Q1	$69.9M	Buy	3,973,245 +1,071,429	+37%	+$16.4M	4.67%	6
2023 Q4	$40.2M	Hold	2,901,816	–	–	3.51%	12
2023 Q3	$39.6M	Buy	2,901,816 +553,544	+24%	+$9.32M	4.63%	8
2023 Q2	$47.9M	Buy	2,348,272 +616,907	+36%	+$12.5M	5.39%	10
2023 Q1	$37.9M	Buy	1,731,365 +1,107,666	+178%	+$22.5M	5.77%	7
2022 Q4	$10.2M	Buy	+623,699	New	+$9.97M	1.54%	23

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Commodore Capital's ELVN Position: Q2 2026 in Review

Commodore Capital held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 3,275,000 shares worth $166M. The position accounts for 9.9% of the portfolio, ranked #2.

Commodore Capital first reported a position in ELVN in Q4 2022 and has held it in 15 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Commodore Capital held 3,275,000 shares of Enliven Therapeutics worth $166M as of Q2 2026.
Commodore Capital left its Enliven Therapeutics share count unchanged in Q2 2026.
Enliven Therapeutics made up 9.9% of Commodore Capital's portfolio in Q2 2026, its #2 holding.
Commodore Capital first reported a position in Enliven Therapeutics in Q4 2022 and has held it in 15 quarters since.
211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.